These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25827235)

  • 1. Editorial Comment from Dr Masumori to Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study comparing finasteride plus tadalafil with finasteride plus placebo.
    Masumori N
    Int J Urol; 2015 Jun; 22(6):589. PubMed ID: 25827235
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial Comment from Dr Oh-oka to Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study comparing finasteride plus tadalafil with finasteride plus placebo.
    Oh-Oka H
    Int J Urol; 2015 Jun; 22(6):588. PubMed ID: 25827197
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study comparing finasteride plus tadalafil with finasteride plus placebo.
    Roehrborn CG; Casabé A; Glina S; Sorsaburu S; Henneges C; Viktrup L
    Int J Urol; 2015 Jun; 22(6):582-7. PubMed ID: 25827166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride.
    Glina S; Roehrborn CG; Esen A; Plekhanov A; Sorsaburu S; Henneges C; Büttner H; Viktrup L
    J Sex Med; 2015 Jan; 12(1):129-38. PubMed ID: 25353053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia.
    Casabé A; Roehrborn CG; Da Pozzo LF; Zepeda S; Henderson RJ; Sorsaburu S; Henneges C; Wong DG; Viktrup L
    J Urol; 2014 Mar; 191(3):727-33. PubMed ID: 24096118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re: Treatment Satisfaction and Clinically Meaningful Symptom Improvement in Men with Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia: Secondary Results from a 6-Month, Randomized, Double-Blind Study Comparing Finasteride plus Tadalafil with Finasteride plus Placebo.
    Kaplan SA
    J Urol; 2016 Oct; 196(4):1220-1. PubMed ID: 27628819
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety and efficacy of the combination of once-daily tadalafil and alpha-1 blocker in Japanese men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A randomized, placebo-controlled, cross-over study.
    Takeda M; Yokoyama O; Yoshida M; Nishizawa O; Hirata K; Nakaoka R; Takita Y; Murakami M
    Int J Urol; 2017 Jul; 24(7):539-547. PubMed ID: 28556284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early improvement of storage or voiding symptoms by tadalafil predicts treatment outcomes in patients with lower urinary tract symptoms from benign prostatic hyperplasia.
    Yokoyama O; Ozeki A; Suzuki N; Murakami M
    Int J Urol; 2018 Mar; 25(3):240-245. PubMed ID: 29094398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
    Dmochowski R; Roehrborn C; Klise S; Xu L; Kaminetsky J; Kraus S
    J Urol; 2010 Mar; 183(3):1092-7. PubMed ID: 20092847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    McVary KT; Roehrborn CG; Kaminetsky JC; Auerbach SM; Wachs B; Young JM; Esler A; Sides GD; Denes BS
    J Urol; 2007 Apr; 177(4):1401-7. PubMed ID: 17382741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men.
    Yokoyama O; Yoshida M; Kim SC; Wang CJ; Imaoka T; Morisaki Y; Viktrup L
    Int J Urol; 2013 Feb; 20(2):193-201. PubMed ID: 22958078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
    Gacci M; Andersson KE; Chapple C; Maggi M; Mirone V; Oelke M; Porst H; Roehrborn C; Stief C; Giuliano F
    Eur Urol; 2016 Jul; 70(1):124-133. PubMed ID: 26806655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tadalafil for the treatment of benign prostatic hyperplasia.
    Mónica FZ; De Nucci G
    Expert Opin Pharmacother; 2019 Jun; 20(8):929-937. PubMed ID: 30901259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of Individual Response to Placebo or Tadalafil 5mg among Men with Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: An Integrated Clinical Data Mining Analysis.
    Fusco F; D'Anzeo G; Henneges C; Rossi A; Büttner H; Nickel JC
    PLoS One; 2015; 10(8):e0135484. PubMed ID: 26284523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of tadalafil on male lower urinary tract symptoms: an integrated analysis of storage and voiding international prostate symptom subscores from four randomised controlled trials.
    Chapple CR; Roehrborn CG; McVary K; Ilo D; Henneges C; Viktrup L
    Eur Urol; 2015 Jan; 67(1):114-122. PubMed ID: 25301757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial.
    Kaplan SA; Lee JY; Meehan AG; Kusek JW;
    J Urol; 2011 Apr; 185(4):1369-73. PubMed ID: 21334655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence-based urology in practice: composite endpoints.
    Lavallée LT; Dahm P; Breau RH
    BJU Int; 2010 Sep; 106(5):610-2. PubMed ID: 20553252
    [No Abstract]   [Full Text] [Related]  

  • 18. Editorial Comment to tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men.
    Gacci M
    Int J Urol; 2013 Feb; 20(2):202. PubMed ID: 22958135
    [No Abstract]   [Full Text] [Related]  

  • 19. Finasteride or dutasteride for the pharmacological treatment for male lower urinary tract symptoms due to benign prostatic hyperplasia?
    Alcántara-Montero A; Brenes-Bermúdez FJ
    Actas Urol Esp; 2016 May; 40(4):268-9. PubMed ID: 26774534
    [No Abstract]   [Full Text] [Related]  

  • 20. Time to onset of clinically meaningful improvement with tadalafil 5 mg once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: analysis of data pooled from 4 pivotal, double-blind, placebo controlled studies.
    Oelke M; Shinghal R; Sontag A; Baygani SK; Donatucci CF
    J Urol; 2015 May; 193(5):1581-9. PubMed ID: 25437533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.